Richard Finkel
Neurology with Special Qualifications in Child Neurology · Memphis, TNNPI 1073547741
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.8%), education and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Novartis Gene Therapies, Inc. (fka Avexis, Inc.) at 36.2% of the total. Among neurology with special qualifications in child neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $805.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$128K
- Sarepta Therapeutics, Inc.$62K
- F. Hoffmann-la Roche AG$52K
- Genentech USA, Inc.$28K
- Biogen$27K
- Novartis Pharma AG$25K
- plus $29K from 8 others
Across 141 payments — averaging $23,815 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$2.1M
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$741K
- Sarepta Therapeutics, Inc.$233K
- Genentech, Inc.$115K
- Novartis$47K
- Hoffmann-la Roche Limited$28K
- plus $46K from 4 others
What the payments were for
- Consulting fees$171,93049%
- Speaking & faculty fees$58,95117%
- Travel & lodging$43,17912%
- Food & beverage$5,6382%
- Education$72,89121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 294 | $127,725 |
| Sarepta Therapeutics, Inc. | 49 | $62,002 |
| F. Hoffmann-la Roche AG | 29 | $52,471 |
| Genentech USA, Inc. | 15 | $28,339 |
| Biogen | 15 | $27,185 |
| Novartis Pharma AG | 4 | $25,486 |
| Novartis | 8 | $19,772 |
| Roche Products Limited | 11 | $8,717 |
| Genentech, Inc. | 8 | $773 |
| Livanova USA, Inc. | 1 | $44 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| Greenwich Biosciences, Inc. | 1 | $22 |
| PTC Therapeutics, Inc. | 1 | $16 |
| Biomarin Pharmaceutical Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOLGENSMA$156,877
- Non-Covered Product$38,296
- EVRYSDI$32,331
- SPINRAZA$21,238
- Elevidys$14,289
- Exondys 51$128
How this compares
$352,588 in reported general payments places this provider in the 95th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.
See all neurology with special qualifications in child neurology providers in Tennessee →
Other neurology with special qualifications in child neurology in Memphis
- James WhelessMemphis$1.2M
- Kathleen Nicole JalandoniMemphis$15K
- Stephen FultonMemphis$2K
- Connor GatewoodMemphis$2K
- Robin JackMemphis$2K
- Marianna Rivas-CoppolaMemphis$1K
- Namrata ShahMemphis$1K
- Ankita GhoshMemphis$1K
- Andrew SchroederMemphis$1K
- Jenny SchmidtMemphis$787
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.